Norepinephrine Uptake Inhibitors

Dopamine Uptake Inhibitors

Dopamine and Norepinephrine Reuptake Inhibitor

Sleepiness

<section class="Section" data-sectioncode="34089-3"><a name="s_1100"></a><a name="section-11"></a><h1>11 DESCRIPTION</h1>SUNOSI contains solriamfetol, a dopamine and norepinephrine reuptake inhibitor (DNRI). Solriamfetol is a phenylalanine derivative with the systematic name (R)-2-amino-3-phenylpropylcarbamate hydrochloride.The molecular formula is C10H15N2O2Cl, and the molecular weight is 230.69.The chemical structure is:<img alt="Chemical Structure" src="sunosi-figure-01.jpg"/>Solriamfetol hydrochloride is a white to off-white solid that is freely soluble in water.SUNOSI tablets are intended for oral administration. Each 75 mg SUNOSI film-coated tablet contains 75 mg solriamfetol (equivalent to 89.3 mg solriamfetol hydrochloride). Each 150 mg SUNOSI film-coated tablet contains 150 mg solriamfetol (equivalent to 178.5 mg solriamfetol hydrochloride). The inactive ingredients are hydroxypropyl cellulose and magnesium stearate. In addition, the film coating contains: iron oxide yellow, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</section>

SUNOSI

solriamfetol

solriamfetol 75 MG Oral Tablet

solriamfetol 150 MG Oral Tablet

Sunosi

solriamfetol 75 MG Oral Tablet [Sunosi]

solriamfetol 150 MG Oral Tablet [Sunosi]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List 

Online Sample Form 

Formulary Information 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity Guide 

Letter of Medical Necessity: Excessive Daytime Sleepiness in Obstructive Sleep Apnea